• S1 Pharmaceuticals Inc., of Jersey City, N.J., said it submitted an investigational new drug application for Phase Ib studies of SIP-104 (Lorexys), its lead candidate for hypoactive sexual desire disorder (HSDD) and female sexual dysfunction. Lorexys is a fixed-dose combination in an oral enteric formulation aimed at treating HSDD both as a standalone and as an adjunct to testosterone therapy.
